Classifications

• • G—PHYSICS
  • G02—OPTICS
  • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
  • G02C7/00—Optical parts
  • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
  • G02C7/04—Contact lenses for the eyes
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
  • C08F230/04—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal
  • C08F230/08—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
  • C08F290/08—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated side groups
  • C08F290/14—Polymers provided for in subclass C08G
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
  • C08F290/08—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated side groups
  • C08F290/14—Polymers provided for in subclass C08G
  • C08F290/148—Polysiloxanes
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
  • C08G77/04—Polysiloxanes
  • C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
  • C08G77/16—Polysiloxanes containing silicon bound to oxygen-containing groups to hydroxy groups
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
  • C08G77/04—Polysiloxanes
  • C08G77/20—Polysiloxanes containing silicon bound to unsaturated aliphatic groups
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
  • C08G77/04—Polysiloxanes
  • C08G77/38—Polysiloxanes modified by chemical after-treatment
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
  • C08K5/00—Use of organic ingredients
  • C08K5/04—Oxygen-containing compounds
  • C08K5/10—Esters; Ether-esters
  • C08K5/101—Esters; Ether-esters of monocarboxylic acids
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
  • C08K5/00—Use of organic ingredients
  • C08K5/04—Oxygen-containing compounds
  • C08K5/13—Phenols; Phenolates
  • C08K5/134—Phenols containing ester groups

Definitions

• the present invention relates to a polysiloxane compound and a method for producing the same.
• Monomers containing siloxane have been known as compounds used in medical materials such as ophthalmic devices.
• 3-[tris(trimethylsiloxy)silyl]propyl methacrylate (TRIS) is widely used as a monomer for ophthalmic devices.
• TRIS tris(trimethylsiloxy)silyl]propyl methacrylate
• Polymers obtained by copolymerizing TRIS with the hydrophilic monomers N,N-dimethylacrylamide and N-vinyl-2-pyrrolidone have the beneficial feature of high oxygen permeability.
• highly hydrophobic siloxane monomers cannot be said to be highly compatible with these hydrophilic monomers, and there is a problem that phase separation occurs when hydrogels that are used as medical materials are produced, resulting in cloudiness. .
• Patent Document 1 describes siloxanes having glycerol methacrylate represented by the following formulas (a) and (a'). Further, Patent Document 2 describes siloxanes having glycerol methacrylate represented by the following formulas (b) and (b'). Further, Patent Document 3 describes a siloxane having an alicyclic methacrylate represented by the following formula (c). These compounds exhibit good hydrophilicity because they have hydroxyl groups in their molecules. Therefore, it has the advantage of being excellent in compatibility with hydrophilic monomers.
• An object of the present invention is to provide a polysiloxane compound suitable for medical materials and a method for producing the same.
• the present invention provides a polysiloxane compound containing one cycloaliphatic hydrocarbon group having 8 to 20 carbon atoms in one molecule, wherein the cycloaliphatic hydrocarbon group is an aliphatic
• a polysiloxane compound having a (meth)acryloxy group and a tertiary hydroxyl group on the ring is provided.
• Such a polysiloxane compound can be suitably used as a medical material.
• the polysiloxane compound is preferably a compound represented by the following formula (1).
• R1 is a methyl group or a hydrogen atom
• A is a group represented by the following formula (2) or (3).
• R is independently a monovalent hydrocarbon group having 1 to 6 carbon atoms
• n is an integer of 1 to 200.
• the dashed line represents a bond.
• R is as described above, a is an integer from 0 to 10, b is an integer from 0 to 10, c is an integer from 0 to 10, provided that a+b+c is 2 or more. represents a hand.
• Such a polysiloxane compound can be suitably used as a medical material.
• A is represented by the above formula (2) and n is an integer of 4 to 100 in the above formula (1).
• Such a polysiloxane compound can be more suitably used as a medical material.
• A is represented by the above formula (3), a is 1, b is 1, and c is 0 in the above formula (1).
• Such a polysiloxane compound can be more suitably used for medical materials.
• R 1 is preferably a methyl group.
• Such a polysiloxane compound of the present invention is preferred.
• each R in formula (2) or (3) is independently a methyl group or a butyl group.
• Such a polysiloxane compound of the present invention is more preferable.
• the present invention also provides a polymer containing a repeating unit derived from polymerization of the (meth)acryloxy group of the polysiloxane compound described above.
• Such a polymer has good compatibility with other compounds having polymerizable groups such as (meth)acryloxy groups.
• the mass ratio of the repeating unit is 10% by mass or more with respect to the total mass of the polymer.
• the present invention also provides a hydrogel or medical material containing the polymer described above.
• the polymer of the present invention can be suitably used for such applications.
• a method for producing a polysiloxane compound represented by the following formula (1) (In formula (1), R1 is a methyl group or a hydrogen atom, and A is a group represented by the following formula (2) or (3).)
• R is independently a monovalent hydrocarbon group having 1 to 6 carbon atoms, and n is an integer of 1 to 200.
• the dashed line represents a bond.
• R is as described above, a is an integer from 0 to 10, b is an integer from 0 to 10, c is an integer from 0 to 10, provided that a+b+c is 2 or more.
• the polysiloxane compound of the present invention has a cyclic aliphatic hydrocarbon group substituted with a tertiary hydroxyl group, it has excellent compatibility with hydrophilic monomers and unexpected hardness when used as a medical material. No increase or loss of flexibility. Furthermore, the (co)polymer containing repeating units derived from the polymerization of the (meth)acryloxy groups of the polysiloxane compound of the present invention has favorable strength.
• the polysiloxane compound of the present invention is useful as a monomer for medical materials.
• the present inventors have made intensive studies to solve the above problems, and found that a polysiloxane compound having a cyclic aliphatic hydrocarbon group substituted with a tertiary hydroxyl group has excellent compatibility with other hydrophilic monomers. I found out. They also found that a (co)polymer of the (poly)siloxane compound and a hydrophilic monomer has excellent flexibility.
• the present invention provides a polysiloxane compound containing one cycloaliphatic hydrocarbon group having 8 to 20 carbon atoms in one molecule, wherein (meth)
• the present invention relates to a polysiloxane compound having an acryloxy group and a tertiary hydroxyl group, and particularly to a polysiloxane compound represented by the following formula (1).
• R1 is a methyl group or a hydrogen atom
• A is a group represented by the following formula (2) or (3).
• R is independently a monovalent hydrocarbon group having 1 to 6 carbon atoms, and n is an integer of 1 to 200.
• the dashed line represents a bond.
• R is as described above, a is an integer from 0 to 10, b is an integer from 0 to 10, c is an integer from 0 to 10, provided that a+b+c is 2 or more. represents a hand.
• the present invention provides a method for producing the polysiloxane compound, a polymer containing repeating units derived from the compound, and a medical material, particularly an ophthalmic device, containing the polymer.
• the present invention relates to a polysiloxane compound containing one cycloaliphatic hydrocarbon group having 8 to 20 carbon atoms in one molecule, wherein a (meth)acryloxy group on the aliphatic ring of the cycloaliphatic hydrocarbon group and a polysiloxane compound having a tertiary hydroxyl group.
• the group having a (meth)acryloxy group and a tertiary hydroxyl group on the aliphatic ring of the cycloaliphatic hydrocarbon group is not particularly limited as long as it has 8 to 20 carbon atoms.
• Group hydrocarbon groups are preferred. (In the above formula, * indicates a free radical bonded to the silicon atom of polysiloxane)
• the polysiloxane compound is preferably a polysiloxane compound represented by the following formula (1).
• R1 is a methyl group or a hydrogen atom
• A is a group represented by the following formula (2) or (3).
• R is independently a monovalent hydrocarbon group having 1 to 6 carbon atoms
• n is an integer of 1 to 200.
• the dashed line represents a bond.
• R is as described above, a is an integer from 0 to 10, b is an integer from 0 to 10, c is an integer from 0 to 10, provided that a+b+c is 2 or more. represents a hand.
• the compound is characterized by having a polysiloxane structure and containing a cycloaliphatic hydrocarbon group in which the linking group between the polysiloxane and the polymerizable group (meth)acryloxy group is substituted with a tertiary hydroxyl group. do.
• this tertiary hydroxyl group is a hydrophilic group, which has steric restrictions. This suppresses side reactions during the reaction, and the polymer ((co)polymer) containing repeating units derived from the polymerization of the (meth)acryloxy group of the polysiloxane compound of the present invention is derived from the directionality of hydrogen bonds.
• the polysiloxane compound of the present invention has high compatibility with hydrophilic monomers, can provide preferable strength in the derived (co)polymer, and also unexpectedly increases hardness and decreases flexibility. do not have.
• R 1 is a methyl group or a hydrogen atom, preferably a methyl group.
• A is a group represented by the above formula (2) or (3), n is an integer of 1 to 200, preferably n is an integer of 4 to 100, more preferably n is 4 to 30 integers.
• a is an integer from 0 to 10
• b is an integer from 0 to 10
• c is an integer from 0 to 10, provided that a+b+c is 2 or more. Also, in formula (3), it is preferred that a is 1, b is 1, and c is 0.
• each R is independently a monovalent hydrocarbon group having 1 to 6 carbon atoms.
• monovalent hydrocarbon groups include alkyl groups such as methyl group, ethyl group, propyl group, n-butyl group, t-butyl group, pentyl group, and hexyl group; cycloalkyl groups such as cyclopentyl group and cyclohexyl group; An aryl group such as a phenyl group and the like are included.
• R is preferably an alkyl group having 1 to 4 carbon atoms, more preferably a methyl group or a butyl group.
• the method for producing a polysiloxane compound of the present invention comprises a compound (unsaturated compound) containing an unsaturated group at the terminal represented by the following formula (4), ( R1 is as above.) a hydrogensiloxane compound represented by the following formula (5) or (6), (R, n, a, b, and c are as described above.) is hydrosilylated in the presence of a catalyst to obtain the compound represented by the above formula (1).
• a compound (formula (4)) having a terminal unsaturated bond and a cyclic aliphatic hydrocarbon group substituted with a tertiary hydroxyl group (formula (4)) is used as a raw material.
• the hydroxyl group possessed by the raw material compound represented by the above formula (4) is a tertiary hydroxyl group present on the cyclohexane ring, so the hydroxyl group is an undesirable side reaction in the hydrosilylation reaction. can be suppressed. Thereby, the polysiloxane compound of the present invention can be obtained with high purity.
• the above hydrosilylation reaction may be carried out according to a conventionally known method.
• 1 molar equivalent or more of the unsaturated compound represented by the formula (4) may be added to the hydrogensiloxane compound represented by the formula (5) or (6) and reacted.
• the reaction temperature is not particularly limited, a temperature that does not exceed the boiling point of the solvent used is preferable. For example, it may be performed at a temperature of about 0°C to about 120°C.
• the hydrosilylation reaction may be carried out in the presence of a solvent, hydrosilylation catalyst, or stabilizer. Solvents, hydrosilylation catalysts and stabilizers are not particularly limited as long as they are conventionally known ones.
• the unsaturated compound is preferably added in an amount of 1 molar equivalent or more relative to the hydrogensiloxane compound. It is more preferably 1.0 to 3.0 molar equivalents, still more preferably 1.1 to 2.0 molar equivalents, and particularly preferably 1.2 to 1.5 molar equivalents.
• 1 molar equivalent or more of the unsaturated compound to the hydrogensiloxane compound, residual hydrogensiloxane compounds and side reactions can be suppressed.
• the upper limit is not limited, it is preferably 3.0 molar equivalents or less from the viewpoint of yield and economy.
• the hydrosilylation catalyst is preferably, for example, a noble metal catalyst, especially a platinum catalyst derived from chloroplatinic acid.
• a noble metal catalyst especially a platinum catalyst derived from chloroplatinic acid.
• a complex (Karstedt catalyst) of 1,1,3,3-tetramethyl-1,3-divinyldisiloxane and chloroplatinic acid neutralized with sodium bicarbonate is more preferable.
• the amount of the hydrosilylation catalyst to be added may be any catalyst amount for advancing the hydrosilylation reaction.
• a complex of 1,1,3,3-tetramethyl-1,3-divinyldisiloxane and chloroplatinic acid neutralized with sodium bicarbonate is converted into a hydrogensiloxane compound represented by formula (5) or (6). It may be used in an amount of 1 ppm to 80 ppm in terms of platinum with respect to the mass of .
• Solvents are, for example, methyl cellosolve, ethyl cellosolve, isopropyl cellosolve, butyl cellosolve, propylene glycol monomethyl ether, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether, polyethylene glycol monomethyl ether, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether and polyethylene glycol.
• glycol ether solvents such as dimethyl ether; ester solvents such as ethyl acetate, butyl acetate, amyl acetate, ethyl lactate and methyl benzoate; aliphatic hydrocarbon solvents such as linear hexane, linear heptane and linear octane; alicyclic hydrocarbon solvents such as ethylcyclohexane; ketone solvents such as acetone, methyl ethyl ketone and methyl isobutyl ketone; aromatic hydrocarbon solvents such as benzene, toluene and xylene; petroleum solvents and the like; and methyl alcohol, ethyl Alcohol solvents such as alcohol, linear propyl alcohol, isopropyl alcohol, linear butyl alcohol, isobutyl alcohol, tert-butyl alcohol, ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and polyethylene glycol are included
• Stabilizers include, for example, phenol-based antioxidants, phosphorus-based antioxidants, amine-based antioxidants, sulfur-based antioxidants, and the like.
• Phenolic antioxidants include, but are not limited to, p-methoxyphenol, di-tert-butyl-p-cresol, pyrogallol, tert-butylcatechol, 4,4-thiobis(3-methyl- 6-tert-butylphenol), 2,2'-methylenebis(4-methyl-6-t-butylphenol), phenol resins, and compounds selected from the group consisting of cresol resins.
• the phosphorus antioxidant is not particularly limited, but for example, tris[2-[[2,4,8,10-tetrakis(1,1-dimethylethyl)dibenzo[d,f][1, 3,2]dioxaphosphepin-6-yl]oxy]ethyl]amine, tris[2-[(4,6,9,11-tetra-tert-butyldibenzo[d,f][1,3, 2]dioxaphosphepin-2-yl)oxy]ethyl]amine, ethylbis(2,4-ditert-butyl-6-methylphenyl)phosphite and the like.
• amine antioxidants include, but are not limited to, tri- or tetra-C1-3 alkylpiperidine or derivatives thereof, bis(2,2,6,6-tetramethyl-4-piperidyl)oxalate, 1 ,2-bis(2,2,6,6-tetramethyl-4-piperidyloxy)ethane, phenylnaphthylamine, N,N'-diphenyl-1,4-phenylenediamine, N-phenyl-N'-cyclohexyl-1 , 4-phenylenediamine and the like.
• sulfur-based antioxidants include, but are not limited to, dilauryl thiodipropionate, distearyl thiodipropionate, and the like.
• the stabilizers may be used singly or in combination of two or more.
• the reaction end point can be confirmed according to a conventionally known method. For example, it can be confirmed by thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), gas chromatography (GC), or the like, by disappearance of the peak of the starting compound.
• purification may be performed according to a conventionally known method.
• the product can be isolated by washing the organic layer with water and then removing the solvent. Alternatively, vacuum distillation, activated carbon treatment, or the like may be used.
• the polysiloxane compound represented by the above formula (1) can be obtained by distilling off the starting material under reduced pressure.
• the polysiloxane compound of the present invention can give a polymer (polymer) containing repeating units derived from (addition) polymerization of (meth)acryloxy groups of the polysiloxane compound.
• the polysiloxane compound of the present invention has good compatibility with other compounds having polymerizable groups such as (meth)acryloxy groups (hereinafter referred to as polymerizable monomers or hydrophilic monomers). Therefore, a colorless and transparent copolymer can be obtained by copolymerizing with a polymerizable monomer. It is also possible to polymerize alone.
• the mixing ratio of the polysiloxane compound of the present invention is It is preferable that the mass ratio of the repeating unit derived from is 10% by mass or more with respect to the total mass of the polymer.
• a repeating unit derived from (addition) polymerization of the (meth)acryloxy group of the polysiloxane compound of the present invention with respect to a total of 100 parts by mass of the polysiloxane compound of the present invention and the polymerizable (hydrophilic) monomer is preferably 10 to 80 parts by mass, more preferably 10 to 60 parts by mass.
• the mass ratio of the repeating unit is 10% by mass or more, the properties of the polysiloxane compound of the present invention are likely to appear.
• polymerizable monomers examples include (meth) acrylic acid, methyl (meth) acrylate, ethyl (meth) acrylate, (poly) ethylene glycol dimethacrylate, polyalkylene glycol mono (meth) acrylate, polyalkylene glycol monoalkyl ether ( Acrylic monomers such as meth)acrylate, trifluoroethyl (meth)acrylate, 2-hydroxyethyl (meth)acrylate, 2,3-dihydroxypropyl (meth)acrylate; N,N-dimethylacrylamide, N,N-diethylacrylamide , N-acryloylmorpholine, N-methyl(meth)acrylamide; other unsaturated aliphatic or aromatic compounds such as N-vinylpyrrolidone, such as crotonic acid, cinnamic acid, vinylbenzoic acid; ) siloxane monomers having a polymerizable group such as an acrylic group. These may be used singly or in combination
• Copolymerization of the polysiloxane compound of the present invention with the other polymerizable monomer may be carried out by a conventionally known method.
• known polymerization initiators such as thermal polymerization initiators and photopolymerization initiators can be used.
• the polymerization initiator include 2-hydroxy-2-methyl-1-phenyl-propan-1-one, azobisisobutyronitrile, azobisdimethylvaleronitrile, benzoyl peroxide, tert-butyl hydroperoxide, cumene. hydroperoxide, 2,2'-azobis(2-methylpropionamidine) dihydrochloride and the like.
• These polymerization initiators can be used alone or in combination of two or more.
• the amount of the polymerization initiator compounded is preferably 0.001 to 2 parts by mass, more preferably 0.01 to 1 part by mass, per 100 parts by mass of the total polymerization components.
• a polymer containing a repeating unit derived from polymerization of the (meth)acryloxy group of the polysiloxane compound of the present invention has excellent hydrophilicity. Moreover, the hydrogel obtained from the polymer has high transparency and strength. Medical materials can also be obtained from the polymer. Therefore, the polysiloxane compound of the present invention is suitable for producing medical materials such as ophthalmic devices, contact lenses, intraocular lenses and artificial corneas.
• the method for producing a medical material using the polymer is not particularly limited, and conventionally known methods for producing a medical material may be followed. For example, when molding into a lens shape such as a contact lens or an intraocular lens, a cutting method, a mold method, or the like can be used.
• Measuring device Agilent gas chromatography (FID detector)
• Capillary column J & W HP-5ms manufactured by Agilent (inner diameter: 0.25 mm x length: 30 m x film thickness: 0.25 ⁇ m)
• Heating program 50°C (5 minutes) ⁇ 10°C/min ⁇ 250°C (holding)
• Carrier gas helium (1.0 ml/min)
• Split ratio 50:1
• Injection volume 1 ⁇ L
• MHMVCH a compound represented by formula (7)
• AHPM isomer mixture of compounds represented by formulas (8A) and (8B)
• C-SiGMA isomer mixture of compounds represented by formulas (9A) and (9B)
• the unsaturated group-containing compound (MHMVCH) containing a tertiary hydroxyl group present on the cyclohexane ring is added to hydrogensiloxane during the hydrosilylation reaction. Since side reactions are suppressed, polysiloxane compounds can be produced with higher purity than unsaturated group-containing compounds (AHPM) having primary and secondary hydroxyl groups.
• the hydrogel using TRIS as a comparative compound has difficulty in transparency (Comparative Example 1).
• hydrogels using the formulas (13A), (13B) and C-SiGMA as comparative compounds have a high elastic modulus and a low maximum elongation (Comparative Examples 2 and 3).
• the hydrogel using the polysiloxane compound of the present invention has excellent transparency, excellent elastic modulus and maximum elongation. That is, the hydrogel using the polysiloxane compound of the present invention provides a medical material having beneficial hydrophilicity and sufficient strength and flexibility.
• the polysiloxane compound of the present invention provides a hydrogel having excellent hydrophilicity and strength.
• the polysiloxane compound of the present invention is useful as a monomer for manufacturing medical materials such as ophthalmic devices, contact lenses, intraocular lenses, artificial corneas, and spectacle lenses.
• the present invention is not limited to the above embodiments.
• the above-described embodiment is an example, and any device having substantially the same configuration as the technical idea described in the claims of the present invention and exhibiting the same effect is the present invention. included in the technical scope of

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicinal Chemistry (AREA)
• Polymers & Plastics (AREA)
• Organic Chemistry (AREA)
• Physics & Mathematics (AREA)
• Ophthalmology & Optometry (AREA)
• General Health & Medical Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• General Physics & Mathematics (AREA)
• Optics & Photonics (AREA)
• Eyeglasses (AREA)
• Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
• Macromonomer-Based Addition Polymer (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=85987367

Family Applications (1)

Country Status (4)

Citations (9)

Family Cites Families (1)

• 2021
  • 2021-10-14 JP JP2021168649A patent/JP7628929B2/ja active Active
• 2022
  • 2022-08-16 EP EP22880630.3A patent/EP4417631A4/en active Pending
  • 2022-08-16 CN CN202280068050.6A patent/CN118076651A/zh active Pending
  • 2022-08-16 WO PCT/JP2022/030943 patent/WO2023062933A1/ja not_active Ceased

Patent Citations (9)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events